image
Healthcare - Biotechnology - NASDAQ - US
$ 0.4649
-2.7 %
$ 6.71 M
Market Cap
-0.29
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one INDP stock under the worst case scenario is HIDDEN Compared to the current market price of 0.465 USD, Indaptus Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one INDP stock under the base case scenario is HIDDEN Compared to the current market price of 0.465 USD, Indaptus Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one INDP stock under the best case scenario is HIDDEN Compared to the current market price of 0.465 USD, Indaptus Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart INDP

image
$1.6$1.6$1.4$1.4$1.2$1.2$1.0$1.0$0.8$0.8$0.6$0.6$0.4$0.4Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
0 REVENUE
0.00%
-15.4 M OPERATING INCOME
6.18%
-15 M NET INCOME
2.60%
-12.3 M OPERATING CASH FLOW
8.07%
0 INVESTING CASH FLOW
0.00%
4.75 M FINANCING CASH FLOW
0.00%
0 REVENUE
0.00%
-4.17 M OPERATING INCOME
-32.77%
-4.13 M NET INCOME
-34.60%
-3.4 M OPERATING CASH FLOW
-35.13%
0 INVESTING CASH FLOW
0.00%
1.8 M FINANCING CASH FLOW
-30.48%
Balance Sheet Indaptus Therapeutics, Inc.
image
Current Assets 6.62 M
Cash & Short-Term Investments 5.79 M
Receivables 0
Other Current Assets 832 K
Non-Current Assets 720 K
Long-Term Investments 0
PP&E 82.2 K
Other Non-Current Assets 638 K
78.85 %11.33 %8.70 %Total Assets$7.3m
Current Liabilities 3.39 M
Accounts Payable 870 K
Short-Term Debt 84.2 K
Other Current Liabilities 2.44 M
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
25.64 %71.88 %Total Liabilities$3.4m
EFFICIENCY
Earnings Waterfall Indaptus Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 0
Gross Profit 0
Operating Expenses 15.4 M
Operating Income -15.4 M
Other Expenses -344 K
Net Income -15 M
00(2m)(2m)(4m)(4m)(6m)(6m)(8m)(8m)(10m)(10m)(12m)(12m)(14m)(14m)(16m)(16m)000(15m)(15m)344k(15m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-380.80% ROE
-380.80%
-204.69% ROA
-204.69%
-381.38% ROIC
-381.38%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Indaptus Therapeutics, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)(50m)(50m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -15 M
Depreciation & Amortization 735
Capital Expenditures 0
Stock-Based Compensation 2.31 M
Change in Working Capital 392 K
Others -81.8 K
Free Cash Flow -12.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Indaptus Therapeutics, Inc.
image
INDP has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 17
6. Ownership
Insider Ownership Indaptus Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company pioneering innovative therapies for cancer and viral infections, announces that its chief medical officer, Roger Waltzman, M.D., M.B.A. will be moderating a panel at the annual CMO360 Summit, being held April 7-8 in Boston. globenewswire.com - 1 month ago
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20 NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today provided an update on key pharmacodynamic findings from the weekly dosing cohort of its ongoing Phase 1 trial of Decoy20. As announced in last week's earnings release, the Company has now enrolled more than 20 patients in the weekly dosing cohort, marking a key milestone in the trial. globenewswire.com - 1 month ago
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that it has advanced to a new expansion arm of its Phase 1b/2 clinical trial of Decoy20. This expansion will evaluate the combination of Decoy20 with BeiGene's PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity. globenewswire.com - 1 month ago
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announces financial results for the fourth quarter and fiscal year ended December 31, 2024 and provides a corporate update. globenewswire.com - 1 month ago
Registration Is Now Open For Tribe Public's Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025 NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ: INDP) announces that Indaptus' CEO, Jeffrey Meckler, will present at Tribe Public's Webinar Presentation and Q&A Event titled “Keys To The Kingdom: Unlocking The Power Of Your Immune System.” The Event is scheduled to begin at 9:00am pacific/12:00pm eastern on Monday, March 17, 2025. To register to join the complimentary event, please visit the Tribe Public LLC at INDP-KEYS.TribePublic.com . globenewswire.com - 1 month ago
Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announced today that it has secured new patent approvals in China, Japan and Israel for its Decoy platform. These patents cover the use of Decoy bacteria compositions for preventing or treating Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) – two diseases that continue to pose major global health challenges. The patents also extend to combination therapies with a variety of both approved and investigational treatments. globenewswire.com - 1 month ago
Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that Michael Newman, Founder and Chief Scientific Officer, will present at the 10th Annual Innate Killer Summit, taking place from March 3-5, 2025, in San Diego, California. Dr. Newman will deliver a scientific presentation on Tuesday, March 4, 2025, titled, “Employing Attenuated & Killed Gram-Negative Bacteria to Induce NK-Mediated Anti-Tumor Immunity. globenewswire.com - 2 months ago
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20 NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced the Company has received Clinical Trial Authorization from Health Canada to initiate its clinical trial for its lead asset, Decoy20. This approval will allow the Company to expand its ongoing U.S. clinical trial, INDP-D101, to Canadian sites, broadening patient recruitment and enhancing its clinical research program. The trial will enroll patients in Canada under the current protocol, which involves weekly dosing of Decoy20. Indaptus also plans to submit an amendment to Health Canada to incorporate its upcoming combination trial, which pairs Decoy20 with Beigene's PD-1 checkpoint inhibitor, tislelizumab. globenewswire.com - 2 months ago
Indaptus Therapeutics Provides Year-End Review and Outlook for 2025 Continued Strong Clinical Progress and Planned New Combination Trial Provide Significant Momentum for 2025 Continued Strong Clinical Progress and Planned New Combination Trial Provide Significant Momentum for 2025 globenewswire.com - 3 months ago
Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that it has entered into securities purchase agreements with investors, including an officer of Indaptus, for the issuance and sale of an aggregate of 1,817,017 of its shares of common stock. In a concurrent private placement, Indaptus has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 1,817,017 of its shares of common stock. The combined effective purchase price for each share of common stock and associated warrants is $1.175. The warrants will have an exercise price of $1.05 per share, will be immediately exercisable upon issuance and have a term of five years from the date of issuance. The closing of the offering is expected to take place on or about November 25, 2024, subject to the satisfaction of customary closing conditions. globenewswire.com - 5 months ago
Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology Preclinical data demonstrates Decoy platform single agent anti-tumor activity and combination-mediated tumor eradication with NSAID, anti-PD1 checkpoint therapy, low dose chemotherapy (LDC) and/or targeted antibody therapy Preclinical data demonstrates Decoy platform single agent anti-tumor activity and combination-mediated tumor eradication with NSAID, anti-PD1 checkpoint therapy, low dose chemotherapy (LDC) and/or targeted antibody therapy globenewswire.com - 5 months ago
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces compelling safety, pharmacokinetics, and biomarker data on its lead compound, Decoy20, at the Society for Immunotherapy of Cancer (SITC) 2024 annual meeting. The data derive from two cohorts (13 patients) of Decoy20 single administration and one cohort (6 patients) of Decoy20 weekly administration in the Company's ongoing Phase 1 clinical trial. globenewswire.com - 5 months ago
8. Profile Summary

Indaptus Therapeutics, Inc. INDP

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 6.71 M
Dividend Yield 0.00%
Description Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
Contact 3 Columbus Circle, New York, NY, 10019 https://indaptusrx.com
IPO Date Aug. 4, 2015
Employees 7
Officers Mr. Jeffrey A. Meckler J.D. Chief Executive Officer & Director Mr. Nir Sassi Chief Financial Officer, Secretary & Treasurer Dr. Michael J. Newman Ph.D. Founder, Chief Scientific Officer & Director Mr. Walt Addison Linscott Esq. Chief Operating Officer Dr. Roger J. Waltzman M.B.A., M.D. Chief Medical Officer